Abstract |
We compared the in vivo and in vitro activities of CS-940, a new fluoroquinolone, with those of a group of other drugs. The activities of CS-940 against gram-positive cocci and gram-negative rods, including methicillin-susceptible Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae, were comparable to those of tosufloxacin, with MICs at which 90% of the strains were inhibited (MIC90s) of 0.5 microg/ml or less. Against methicillin-resistant S. aureus, CS-940 was as active as tosufloxacin, with a MIC90 of 16 microg/ml. The efficacy of CS-940 against murine respiratory infections due to S. pneumoniae or Haemophilus influenzae was better than those of tosufloxacin and sparfloxacin. The efficacy of oral doses of CS-940 reflected not only potent in vitro activity but also a high transmigration ratio from the bloodstream to lung tissues.
|
Authors | S Miyazaki, H Domon, K Tateda, A Ohno, Y Ishii, T Matsumoto, N Furuya, K Yamaguchi |
Journal | Antimicrobial agents and chemotherapy
(Antimicrob Agents Chemother)
Vol. 41
Issue 11
Pg. 2582-5
(Nov 1997)
ISSN: 0066-4804 [Print] United States |
PMID | 9371375
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Anti-Infective Agents
- Fluoroquinolones
- Piperazines
- Quinolones
- CS 940
|
Topics |
- Animals
- Anti-Infective Agents
(pharmacokinetics, therapeutic use)
- Area Under Curve
- Female
- Fluoroquinolones
- Humans
- Mice
- Mice, Inbred CBA
- Microbial Sensitivity Tests
- Piperazines
(pharmacokinetics, therapeutic use)
- Quinolones
(pharmacokinetics, therapeutic use)
- Respiratory Tract Infections
(drug therapy)
- Staphylococcus
(drug effects)
|